SCHEMBL731007

SCHEMBL731007

CCOc1cc(C(=O)O)cc(OC)c1-c1cnn(C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.49
CNR2 P34972 1/20 0.47
PLAU P00749 1/20 0.43
AAK1 Q2M2I8 1/20 0.43
MAP4K4 O95819 1/20 0.42
ERN1 O75460 1/20 0.42
IGF1R P08069 1/20 0.41
CHEK1 O14757 1/20 0.41
LOXL2 Q9Y4K0 3/20 0.40
FGFR2 P21802 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
KMT2A Q03164 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA3 P07451 1/20 0.40
PKM P14618 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL731308 0.95 MAP4K4 (0.45) TSHRPLAUAAK1MAP4K4CHEK1
SCHEMBL733242 0.91 CNR2 (0.55) CNR2PLAUAAK1MAP4K4ERN1
SCHEMBL730899 0.89 AAK1 (0.44) TSHRCNR2PLAUAAK1ERN1
SCHEMBL731379 0.85 PDK2 (0.45) TSHRPLAUAAK1ERN1FGFR2
SCHEMBL731831 0.80 TSHR (0.39) TSHR
SCHEMBL730596 0.79 TSHR (0.41) TSHR
SCHEMBL732989 0.79 MAP4K4 (0.54) TSHRAAK1MAP4K4CHEK1
SCHEMBL731170 0.76 PLAU (0.39) PLAUAAK1ERN1FGFR2
SCHEMBL30668612 0.74 USP30 (0.60) TSHRPLAUAAK1MAP4K4ERN1
SCHEMBL156288 0.74 USP30 (0.60) TSHRPLAUAAK1MAP4K4ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 TSHR 680/4885CNR2 503/4885PLAU 4523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.